Nivolumab activity in advanced refractory malignant peritoneal mesothelioma

Eur J Cancer. 2021 Feb:144:386-388. doi: 10.1016/j.ejca.2020.11.024. Epub 2020 Dec 25.

¹ Department of Medical Oncology, Institut Curie, PSL Research University, Paris, 75248, France.
² Department of Pathology, Institut Curie, PSL Research University, Paris, 75248, France.
³ Genetic Somatic Unit, Institut Curie, PSL Research University, Paris, 75248, France.
⁴ Department of Radiology, Institut Curie, PSL Research University, Paris, 75248, France.
⁵ Department of Medical Oncology, Institut Curie, PSL Research University, Paris, 75248, France; Cancer, Heterogeneity, Instability and Plasticity (CHIP), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, INSERM U830, Paris, 75248, France. Electronic address: sarah.watson@curie.fr.

No abstract available

Keywords: Immunotherapy; Malignant peritoneal mesothelioma; Next generation sequencing; Nivolumab.

Publication types